PrecisionLife and Ovation have entered a collaboration agreement to commercialize a GLP-1 stratification test platform combining AI-driven genomic analytics with real-world clinical data, targeting an H2 2026 launch. The UK-based precision medicine firm PrecisionLife will apply its combinatorial analytics engine to Ovation's multi-omic GLP-1 receptor agonist dataset, with the goal of producing genetic biomarker signatures that predict individual patient response to GLP-1 therapies including semaglutide and tirzepatide. The partnership plans two commercial outputs: a laboratory developed test for clinical use and a direct-to-consumer GLP-1 DNA test. Both companies are privately held.
Financial terms were not disclosed.
Deal context
The scientific premise of the collaboration rests on a finding from a preliminary study conducted using Ovation's dataset: the companies report that genetic markers associated with glycemic control, measured by HbA1c, are distinct from those associated with weight loss, measured by BMI, in a real-world GLP-1-treated population. PrecisionLife describes its platform as capable of identifying combinatorial genetic patterns across complex chronic disease datasets, and the company states the approach has been applied across more than 60 diseases. The companies say the preliminary analysis also identified biological mechanisms associated with GLP-1 response that overlap with pathways previously implicated in addiction and neuroplasticity, though these findings have not been independently validated or published in peer-reviewed literature. Over the next six months, PrecisionLife plans to reproduce and refine the biomarker findings in additional Ovation cohorts, including validation against real-world outcomes for specific GLP-1 agents. No clinical trial identifiers, regulatory designations, or published data are associated with the platform at this stage.